ESR1 and breast carcinoma: Drugs that target ERα pathways are highly effective in the treatment of ER+ breast cancer; however, de novo or acquired resistance to these agents (endocrine resistance) affects a large proportion (>30%) of patients and is the major cause of breast cancer mortality.